Welcome to our dedicated page for Stereotaxis news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis stock.
Stereotaxis, Inc. (STXS) is a global leader in innovative robotic technologies aimed at improving the treatment of arrhythmias and endovascular procedures. The company's mission focuses on the discovery, development, and delivery of advanced robotic systems, instruments, and information solutions tailored for the interventional laboratory. By leveraging cutting-edge innovations, Stereotaxis helps physicians provide superior patient care with robotic precision and safety, streamline lab efficiency, and enhance procedural information integration.
Stereotaxis boasts over 100 issued patents that form the backbone of its platform. The core components of its systems have received regulatory clearance in various regions including the United States, European Union, Japan, Canada, and China, among others. This broad regulatory approval underscores the global trust and reliance on Stereotaxis' technology.
The company's revenue streams are diversified across systems, disposables, royalties, and subleases, with a significant portion generated from disposables, services, and accessories. Notably, the majority of its revenue is derived from the United States.
Through continuous innovation and dedication to serving the medical community, Stereotaxis remains at the forefront of robotic medical technology, making significant strides in improving procedural outcomes and operational efficiencies in healthcare settings worldwide.
For the latest updates and more information, visit Stereotaxis.
Stereotaxis (NYSE: STXS) and MicroPort EP announced that China's NMPA has approved the Magbot™ Magnetic Navigation Ablation Catheter. This single-use magnetic saline-irrigated radiofrequency ablation catheter works exclusively with Stereotaxis' robotic systems and MicroPort EP's Columbus™ 3D EP Mapping System.
The Magbot™ features advanced design elements including a unique six-electrode configuration for enhanced safety and reduced fluoroscopy needs. It's approved for treating drug-resistant persistent atrial fibrillation and other cardiac conditions. The catheter enables precise positioning with millimeter-level accuracy using low-intensity magnetic fields.
MicroPort EP will handle the commercial launch in China through its existing sales team, with Stereotaxis sharing in the proceeds from Magbot™ adoption.
Stereotaxis (NYSE: STXS) announced that its latest GenesisX robotic system is being featured at Neusoft Medical Systems' booth during RSNA 2024, the world's premier radiology forum in Chicago. The system is being showcased alongside Neusoft's NeuAngio 30F fluoroscopy system, marking a growing collaboration between the companies to integrate and commercialize complementary technologies.
GenesisX builds upon Robotic Magnetic Navigation technology, aiming to enhance precision, efficiency, and safety in endovascular procedures while reducing hospital adoption barriers. The event, attended by over 50,000 professionals from 150+ countries, represents the first public showcase of the GenesisX system.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announces its participation in the Piper Sandler 36th Annual Healthcare Conference. Chairman and CEO David Fischel will present the company's technology and growth strategy on December 5, 2024, at 2:00 pm ET, and will be available for one-on-one meetings.
The company's innovative robotics technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions. Stereotaxis focuses on developing robotic systems, instruments, and information solutions for the interventional laboratory, aiming to enhance physician care delivery with robotic precision and safety.
Stereotaxis (NYSE: STXS) and MicroPort EP announced that China's National Medical Products Administration (NMPA) has approved the Genesis RMN® System. This approval enables the commercialization of advanced robotic technology for minimally-invasive procedures in China. MicroPort EP will lead the commercial launch through its existing electrophysiology sales teams. The approval is part of a broader collaboration between both companies, announced in August 2021, which includes development and integration of robotic systems, navigated catheters, and MicroPort EP's Columbus™ 3D mapping system. The Genesis system, already FDA-cleared and CE-marked, has been used to treat thousands of patients in the US and Europe.
Stereotaxis (NYSE: STXS) announced that Hospital da Luz in Lisbon, Portugal has successfully implemented and treated its first patients using the Genesis Robotic Magnetic Navigation (RMN) System. Hospital da Luz Lisboa, part of Portugal's largest health group Luz Saude, is a university hospital that has performed over 4,000 robotic cardiac ablation procedures. The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through minimally invasive cardiac ablation procedures with robotic precision and safety.
Stereotaxis (NYSE: STXS) reported Q3 2024 financial results with total revenue of $9.2 million, up 18% year-over-year. System revenue was $4.4 million and recurring revenue was $4.8 million. The company achieved CE Mark for GenesisX robotic system and expects European CE Mark approval for MAGiC ablation catheter soon. Gross margin was 45%, with operating loss of $6.3 million. The quarter saw partial revenue recognition of three Genesis systems and orders for two additional systems. Cash balance stood at $11.0 million as of September 30, 2024, increasing to $13.3 million by end of October, with no debt.
Stereotaxis (NYSE: STXS) announced that the University of Kansas Health System has successfully implemented and treated its first patients using the Genesis Robotic Magnetic Navigation (RMN) System. The Genesis System represents the latest advancement in robotic technology for cardiac ablation procedures, treating arrhythmias with robotic precision and safety. Dr. Seth Sheldon, Cardiac Electrophysiologist at the facility, highlighted how the system's precision and stability enable delivery of personalized treatments, improving patient outcomes and quality of life. The technology has been used to treat over 150,000 patients globally.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, announced it will release its 2024 third quarter financial results on November 11, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments. Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced its participation in the Society for Cardiac Robotic Navigation's Annual Meeting on October 28-29 in Lisbon, Portugal. The conference will feature over forty physicians from across the globe, showcasing Stereotaxis' robotic technologies in presentations, panels, and demonstrations.
Key topics include:
- Artificial intelligence and robotic automation in cardiology
- Clinical experience with the MAGiC ablation catheter and Abbott's EnSite X mapping system
- Robotic catheter innovations for high-density mapping and pulsed field ablation
- Advancements in Genesis and GenesisX robotic systems
- Alternative access techniques from the arm
- Best practices for robotics in complex arrhythmia treatment
David Fischel, Stereotaxis Chairman and CEO, expressed excitement about the conference, noting the growing importance of robotics in advancing cardiology.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences. David Fischel, Chairman and CEO, will represent the company at both events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 11th, 2024, where he will present a company overview at 12:30 pm EST and be available for one-on-one meetings.
2. Lake Street 8th Annual Best Ideas Growth Conference on September 12, 2024, where he will be available for one-on-one meetings.
Fischel expressed appreciation for the opportunity to share Stereotaxis' ongoing technological, commercial, and strategic progress with investors. Interested parties can arrange meetings through conference registration.
FAQ
What is the current stock price of Stereotaxis (STXS)?
What is the market cap of Stereotaxis (STXS)?
What does Stereotaxis, Inc. specialize in?
What is the mission of Stereotaxis, Inc.?
Where has Stereotaxis' technology received regulatory clearance?
What are the main revenue streams for Stereotaxis, Inc.?
Who are the key executives at Stereotaxis, Inc.?
How does Stereotaxis' technology benefit physicians?
How many patents does Stereotaxis hold?
What geographic region generates the majority of Stereotaxis' revenue?
What types of procedures are enhanced by Stereotaxis' technology?